ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "fibromyalgia"

  • Abstract Number: 1290 • ACR Convergence 2023

    Development of a Genetic Risk Score for Pain in Rheumatoid Arthritis

    Katie McMenamin1, Kristin Wipfler2, Austin Wheeler3, Grant Cannon4, K Wysham5, Brian Sauer6, Bryant England3, Kaleb Michaud3, Ted R Mikuls7 and Joshua Baker8, 1Boston University, Boston, MA, 2FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 3University of Nebraska Medical Center, Omaha, NE, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5VA Puget Sound/University of Washington, Seattle, WA, 6Salt Lake City VA/University of Utah, Salt Lake City, UT, 7Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 8University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Pain in rheumatoid arthritis (RA) is multifactorial and involves processes beyond inflammation such as peripheral and central pain processing. Several genes have been associated…
  • Abstract Number: 1833 • ACR Convergence 2023

    Development of a Polygenic Risk Model for Therapeutic Response to Bedtime Sublingual Cyclobenzaprine (TNX-102 SL*) in Fibromyalgia Based on Polygenic Single Nucleotide Polymorphism (SNP)-Count Scores

    Jeffrey Rosenfeld1, Greta Linse2, Sally Slipher2, Candace Flint3, Annie Iserson3, Herbert Harris4, Jean Engels3, Gregory Sullivan5 and Seth Lederman6, 1Tonix Pharmaceuticals, Chatham, NJ, 2Montana State University, Bozeman, MT, 3Tonix Pharmaceuticals, New York, NY, 4Tonix Pharmaceuticals, Chapel Hill, NC, 5Tonix Pharmaceuticals Inc, Chatham, NJ, 6Tonix Pharmaceuticals, South Dartmouth, MA

    Background/Purpose: Fibromyalgia (FM) is characterized by widespread pain, non-restorative sleep, fatigue, and cognitive dysfunction. TNX-102 SL is a sublingual cyclobenzaprine tablet designed for daily use…
  • Abstract Number: 1227 • ACR Convergence 2022

    Impact of Pain Sensitivity and Expectations on Predicting Response to Acupuncture in Fibromyalgia

    Anne Murphy1, Henry Buchtel1, Erin Zhan1, Steven E Harte1, Ishtiaq Mawla1, Eric Ichesco1, Tony Larkin1, Vitaly Napadow2 and Richard E Harris1, 1University of Michigan, Ann Arbor, MI, 2Harvard Medical School, Boston, MA

    Background/Purpose: Fibromyalgia (FM) is a common chronic pain condition for which acupuncture treatment is increasingly utilized. However, there is no universally accepted measure to predict…
  • Abstract Number: 1228 • ACR Convergence 2022

    Distinctive Alterations in the Functional Anatomy of the Cerebral Cortex in Pain-sensitized Osteoarthritis and Fibromyalgia Patients

    Jesús Pujol1, Fabiola Ojeda1, Laura Blanco-Hinojo1, Andrea Doreste1, Gerard Martinez-Vilavella1, Víctor Pérez-Solá1, Joan Deus2 and Jordi Monfort1, 1Hospital del Mar, Barcelona, Spain, 2Autonomous University of Barcelona, Barcelona, Spain

    Background/Purpose: Fibromyalgia is a primary pain sensitization disorder showing augmented pain sensitivity with no apparent origin. In contrast, secondary sensitization often occurs in knee osteoarthritis…
  • Abstract Number: 1359 • ACR Convergence 2022

    Usability and Acceptability of a Digital Behavioral Therapy for the Management of Fibromyalgia

    Nelson Mitchell1, Yifei Dai2, Michael Rosenbluth3, Allison Kraus1, Maggie Avila1, Aabha Morey1, Michael Gendreau4, Nicolette Vega1, Zunera Ghalib1 and Brian Keefe5, 1Swing Therapeutics, San Francisco, 2Swing Therapeutics, Gainesville, FL, 3Swing Therapeutics, San Francisco, CA, 4GENDREAU CONSULTING, LLC, Poway, CA, 5Swing Therapeutics, New York, NY

    Background/Purpose: Cognitive behavioral therapy (CBT) is considered a gold-standard treatment with demonstrated level 1A evidence for management of fibromyalgia (FM). Acceptance and Commitment Therapy (ACT),…
  • Abstract Number: 1775 • ACR Convergence 2022

    More Than Half of Patients with Osteoarthritis Have Positive Screening for Fibromyalgia And/or Depression, Feasibly Assessed in Routine Care on Indices Within a Single MDHAQ (multidimensional Health Assessment Questionnaire)

    Theodore Pincus1, Kathryn Gibson2, Juan Schmukler1, Tengfei Li3 and Joel Block1, 1Rush University Medical Center, Chicago, IL, 2Liverpool Hospital, Sydney, Australia, 3Georgetown University, Washington, DC

    Background/Purpose: Osteoarthritis (OA) patients may have widely divergent scores for pain severity vs X-ray joint damage, indicating that elevated OA pain 0-10 visual numeric scale…
  • Abstract Number: 0263 • ACR Convergence 2022

    DAS28 (disease Activity Score) Elevations in Patients with Rheumatoid Arthritis (RA) Who Have Comorbid Fibromyalgia Are Explained by Elevated Tender Joint Counts as Much as by Elevated Patient Global Assessment

    Sandhya shri Kannayiram1, Juan Schmukler2, Nicola Goodson3 and Theodore Pincus2, 1John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, 2Rush University Medical Center, Chicago, IL, 3University Hospital Aintree, Liverpool, United Kingdom

    Background/Purpose: Several reports indicate that patient global assessment (PATGL) may elevate DAS28 (disease activity score 28) and/or other indices in patients with rheumatoid arthritis (RA),…
  • Abstract Number: 1908 • ACR Convergence 2022

    Should Osteoarthritis Patients with Pain Scores More Than 8/10 Be Analyzed Separately or Excluded from Clinical Trial Protocols, as 72% Screen Positive for Fibromyalgia And/or Depression on a Multidimensional Health Assessment Questionnaire (MDHAQ)?

    Juan Schmukler1, Kathryn Gibson2, Tengfei Li3, Joel Block1 and Theodore Pincus1, 1Rush University Medical Center, Chicago, IL, 2Liverpool Hospital, Sydney, Australia, 3Georgetown University, Washington, DC

    Background/Purpose: Most osteoarthritis (OA) clinical trial protocols require a 0-10 pain visual numeric scale (VNS) or other quantitative pain score of 4/10 or more for…
  • Abstract Number: 0697 • ACR Convergence 2022

    Are Fibromyalgia and Depression as Common as Any Primary Diagnosis in Routine Rheumatology Care, Albeit as Secondary Diagnoses, but Which May Confound Clinical Assessment?

    Theodore Pincus1, Kathryn Gibson2, Juan Schmukler1, Tengfei Li3 and Joel Block1, 1Rush University Medical Center, Chicago, IL, 2Liverpool Hospital, Sydney, Australia, 3Georgetown University, Washington, DC

    Background/Purpose: Fibromyalgia (FM) and depression (DEP) are common comorbidities of all reported primary rheumatic diagnoses, easily recognized in many patients, but often underestimated, particularly in…
  • Abstract Number: 1945 • ACR Convergence 2022

    Determinants of Patient’s Global Assessment of Disease Severity and Predictors of Disease Course in Juvenile Fibromyalgia

    Clara Malattia1, Claudio Lavarello1, Alessandra Alongi2, Benedetta Mori2, Anna Ronchetti3, Lino Nobili4, Lorenzo Chiarella5, Elena Pescio6, Angelo Ravelli7 and Marco Gattorno8, 1Pediatric Clinic and Rheumatology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy,Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal Infantile Sciences (DINOGMI) University of Genoa, Genova, Italy, 2Department of Pediatric Emergency, ARNAS Civico-Di Cristina-Benfratelli, Palermo, Italy, 3Physical Medicine and Rehabilitation Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy, 4Child Neuropsychiatry Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy,Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal Infantile Sciences (DINOGMI) University of Genoa, Genova, Italy, 5Child Neuropsychiatry Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy,Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal Infantile Sciences (DINOGMI) University of Genoa, Genova, 6Psychology Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy, 7Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal Infantile Sciences (DINOGMI) University of Genoa, Italy,Scientific Direction, IRCCS Istituto Giannina Gaslini, Genova, Italy, 8Pediatric Clinic and Rheumatology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy

    Background/Purpose: Juvenile Fibromyalgia Syndrome (JFS) is a disabling condition characterized by widespread musculoskeletal pain, fatigue and mood disturbances, which impact significantly on patients' quality of…
  • Abstract Number: 0728 • ACR Convergence 2022

    Racial Disparities in Pain: Severity, Interference with Function, and Response to Guided Imagery

    Victoria Menzies and Molly Jacobs, University of Florida, Gainesville, FL

    Background/Purpose: Fibromyalgia syndrome (FMS) is a condition characterized by diffuse, widespread, persistent musculoskeletal pain in multiple regions of the body. While FMS is more prevalent…
  • Abstract Number: 2233 • ACR Convergence 2022

    Machine Learning Uncovers Novel mRNAs Expressed in Fibromyalgia

    Lena Kolb1, Mark Rudolph1, Alan Kivitz2, Scott Rey1, Roberta Alexander1, Anja Kammesheidt3 and Geoffrey Stephens1, 1Exagen, Inc., Vista, CA, 2Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, 3self, Laguna Beach, CA

    Background/Purpose: Fibromyalgia is a debilitating pain condition that affects roughly 12 million people in the United States. Although preliminary diagnostic criteria have been established by…
  • Abstract Number: 0733 • ACR Convergence 2022

    Median Patient Global Assessment Varies Far More According to FAST4 (fibromyalgia Assessment Screening Tool) and MDS2 (MDHAQ Depression Screen) on a Single MDHAQ (multidimensional Health Assessment Questionnaire) Than According to Primary Diagnosis

    Theodore Pincus1, Kathryn Gibson2, Juan Schmukler1, Tengfei Li3 and Joel Block1, 1Rush University Medical Center, Chicago, IL, 2Liverpool Hospital, Sydney, Australia, 3Georgetown University, Washington, DC

    Background/Purpose: Patient global assessment (PATGL) is a component of DAS28 (disease activity score 28) and CDAI (clinical disease activity index) to assess patients with rheumatoid…
  • Abstract Number: 2235 • ACR Convergence 2022

    Clinical Impact of a Digital Behavioral Therapy for Fibromyalgia Management in a Decentralized Trial

    Yifei Dai1, Michael Rosenbluth2, Michael Gendreau3, Nicolette Vega4, Zunera Ghalib4, Allison Kraus4 and Brian Keefe5, 1Swing Therapeutics, Gainesville, FL, 2Swing Therapeutics, San Francisco, CA, 3GENDREAU CONSULTING, LLC, Poway, CA, 4Swing Therapeutics, San Francisco, 5Swing Therapeutics, New York, NY

    Background/Purpose: Cognitive behavioral therapy (CBT) has demonstrated level 1A evidence for management of fibromyalgia (FM). Acceptance and Commitment Therapy (ACT), a form of CBT, has…
  • Abstract Number: 1216 • ACR Convergence 2022

    Subclinical Vascular Disease Is More Prevalent in above-30 Adult Fibromyalgia: A Preliminary Report of a Hospital-based Cross-sectional Study from South India

    Salil Ganu, C. B. Mithun and Jyothi Visalakshy, Amrita Institute of Medical Sciences, Kochi, India

    Background/Purpose: Fibromyalgia is known to be associated with cardiovascular events and mortality. We aimed to compare the prevalence of subclinical atherosclerosis (SAT), a surrogate marker…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 23
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology